Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionLido Advisors, LLC
Latest Disclosed Ownership43,511 shares
Latest Disclosed Value $ 19,429,997
Lido Advisors, LLC ownership in 1VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Lido Advisors, LLC filed a 13F-HR form disclosing ownership of 43,511 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $16,516,776 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 53,597 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -18.82% during the quarter. The current value of the position is $15,938,079 USD.

Lido Advisors, LLC has a history of taking positions in derivatives of the underlying security (1VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,511 -10,086 -18.82 19,430 -12.04 0.0566
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 53,597 -98 -0.18 22,089 5.04 0.0660
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 53,695 7,873 17.18 21,030 3.08 0.0659
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,822 11,590 33.86 20,400 22.92 0.0795
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,232 2,626 8.31 16,597 30.40 0.0747
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,606 7,207 29.54 12,728 12.16 0.0579
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,399 335 1.39 11,348 0.60 0.0566
2024-08-15 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,064 530 2.25 11,280 14.66 0.0628
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,534 -89 -0.38 9,837 2.34 0.0579
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,623 -15,330 -39.36 9,612 -29.04 0.0649
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 38,953 21,761 126.58 13,546 123.88 0.1031
2023-08-09 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,192 -7,087 -29.19 6,050 -20.90 0.0432
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,279 -3,953 -14.00 7,649 -6.17 0.0744
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,232 12,234 76.47 8,153 76.03 0.0994
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,998 11,851 285.77 4,631 296.49 0.0582
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,147 92 2.27 1,168 10.40 0.0155
2022-05-17 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,055 712 21.30 1,058 44.14 0.0118
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,343 1,013 43.48 734 73.93 0.0080
2022-02-15 2021-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 2,330 295 14.50 422 2.93 0.0059
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,968 2,933 423 0.0055
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,035 216 11.87 410 4.86 0.0057
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,819 -130 -6.67 391 -15.00 0.0114
2021-02-08 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,949 130 7.15 460 -7.07 0.0155
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,819 211 13.12 495 6.00 0.0212
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,608 128 8.65 467 32.67 0.0227
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,480 45 3.14 352 12.10 0.0227
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,435 25 1.77 314 31.38 0.0183
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,410 15 1.08 239 -6.27 0.0186
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,395 26 1.90 255 1.59 0.0216
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,369 -22 -1.58 251 9.13 0.0224
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,391 18 1.31 230 -12.88 0.0318
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,373 49 3.70 264 17.33 0.0341
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,324 -1,333 -50.17 225 -48.04 0.0341
2018-05-09 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,657 2,657 433 0.0749
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM Put 300 0.00 134 -2.21 n/a n/a n/a
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM Put 300 0.00 136 16.24 n/a n/a n/a
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM Put 300 0.00 117 -12.03 n/a n/a n/a
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM Put 300 -76.92 134 -78.89 n/a n/a n/a
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM Put 1,300 0.00 630 20.46 n/a n/a n/a
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM Put 1,300 0.00 524 -13.41 n/a n/a n/a
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM Put 1,300 0.00 605 -0.82 n/a n/a n/a
2024-08-15 2024-06-30 13F VERTEX PHARMACEUTICALS COM Put 1,300 -13.33 609 -2.87 n/a n/a n/a
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM Put 1,500 0.00 627 2.79 n/a n/a n/a
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM Put 1,500 0.00 610 17.08 n/a n/a n/a
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM Put 1,500 522 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.